CMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filing
Multiple analysts reiterated optimism on CMPS stock after the company announced 26-week data from its second late-stage trial of COMP360 in treatment-resistant depression.
Read the full articleYou might also wanna read
Chip stocks boost global markets ahead of SK Hynix blockbuster US debut
European shares were muted on Friday, with the pan-European STOXX 600 up 0.1%, remaining on track for a weekly loss that could snap a four-
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across
Prediction: TSMC Stock Is Going to Soar After July 16
The foundry giant has underperformed the semiconductor sector this year, but it could step on the gas after its Q2 results are released next
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
The company recently wowed investors with clinical trial results.
Dr Reddy's extends slide as semaglutide setback threatens first-mover edge
Supply disruption has cast doubt on Dr Reddy's ability to capitalise on its early lead, with brokerages warning that prolonged delay could a
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry pa
Comments
Sign in to join the conversation.
No comments yet. Be the first.